<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063579</url>
  </required_header>
  <id_info>
    <org_study_id>UW18-022</org_study_id>
    <nct_id>NCT04063579</nct_id>
  </id_info>
  <brief_title>Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>Cardiac Magnetic Resonance Assessment for Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study that aims to define the utility of cardiac magnetic resonance
      feature tracking (CMR-FT) as a non-invasive quantification tool to assess diastolic
      functionality in patients with Heart Failure with preserved ejection fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the increasing prevalence and poor prognosis of HFpEF worldwide, it is facing
      diagnostic challenges due to its non-specific clinical manifestations. Currently,
      echocardiography serves as the main diagnostic tool, but alternatives are limited to less
      preferred invasive procedures in most clinical situations.

      It is therefore proposed to investigate HFpEF using cardiovascular magnetic resonance imaging
      (CMR), as an alternative non-invasive diagnostic tool which carries lower risk than invasive
      procedures.

      The study aims to: (1) access the utility of CMR-FT as a new indicator to diagnose diastolic
      dysfunction by differentiating HFpEF patients from non-HFpEF patient and normal volunteers.
      (2) Compare accuracy of CMR-FT to CMR tagging and phase contrast imaging.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of feature tracking diastolic strain rate to diagnose diastolic dysfunction by differentiating HFpEF patients from the non-HFpEF patients and normal volunteers</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rate of cardiac catheterisation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unexpected findings by CMR (eg. Cardiac amyloidosis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Patients with heart failure with preserved ejection fraction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-heart failure patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization</intervention_name>
    <description>Imaging, blood tests, LV pressure measurement</description>
    <arm_group_label>Non-heart failure patients</arm_group_label>
    <arm_group_label>Patients with heart failure with preserved ejection fraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)</intervention_name>
    <description>Imaging and Blood tests</description>
    <arm_group_label>Normal Volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting with symptoms and signs suggestive of HFpEF

          -  Patients undergoing coronary catheterisation for stable chest pain with no evidence of
             diastolic dysfunction, heart failure, infarct, left ventricular ejection fraction &lt;50%
             or significant coronary artery disease (ie. &gt;50% narrowing of one or more coronary
             arteries)

          -  Volunteers must be asymptomatic with no cardiac risk factors and no previous cardiac
             history

        Exclusion Criteria:

          -  Patients suspected to have HFpEF but echocardiography and/or invasive pressure
             measurements do not confirm diagnosis of HFpEF.

          -  Significant underlying ischaemia based on clinical history and non-invasive imaging or
             catheter coronary angiography if indicated.

          -  Contraindication to CMR study

          -  Estimated glomerular filtration rate &lt;30 ml/min/1.73 m2

          -  More than moderate valvular disease

          -  Severe pulmonary disease (ie. FEV1 &lt;- 50% predicted)

          -  Cardiomyopathy

          -  Constrictive pericarditis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Yen Ng, BMBS</last_name>
    <phone>22554524</phone>
    <phone_ext>4524</phone_ext>
    <email>myng2@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Yen Ng, BMBS</last_name>
      <phone>22554524</phone>
      <email>myng2@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

